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Abstract A prolonged QT interval is an important risk
factor for ventricular arrhythmias and sudden cardiac death.
QT prolongation can be caused by drugs. There are multiple
risk factors for drug-induced QT prolongation, including
genetic variation.QTprolongation is one of themost common
reasons for withdrawal of drugs from the market, despite the
fact that these drugs may be beneficial for certain patients and
not harmful in every patient. Identifying genetic variants
associated with drug-induced QT prolongation might add to
tailored pharmacotherapy and prevent beneficial drugs from
being withdrawn unnecessarily. In this review, our objective
was to provide anoverviewof the genetic backgroundof drug-
induced QT prolongation, distinguishing pharmacokinetic
and pharmacodynamic pathways. Pharmacokinetic-mediated
genetic susceptibility is mainly characterized by variation in
genes encoding drug-metabolizing cytochrome P450
enzymes or drug transporters. For instance, the P-glycoprotein
drug transporter plays a role in the pharmacokinetic suscep-
tibility of drug-induced QT prolongation. The pharmacody-
namic component of genetic susceptibility is mainly
characterized by genes known to be associated with QT
interval duration in the general population and genes in which
the causal mutations of congenital long QT syndromes are
located. Ethnicity influences susceptibility to drug-induced
QT interval prolongation, with Caucasians being more sen-
sitive than other ethnicities. Research on the association
between pharmacogenetic interactions and clinical endpoints
such as sudden cardiac death is still limited. Future studies in
this area could enable us to determine the risk of arrhythmias
more adequately in clinical practice.
Key Points
Both pharmacokinetic and pharmacodynamic factors
have been identified to influence susceptibility for
drug-induced QT interval prolongation, but only few
have been consistently associated.
Caucasians seem to be more sensitive to drug-
induced QT interval prolongation than other
ethnicities and therefore ethnicity might be an
important factor to take into account when
determining risk of ventricular arrhythmias.
Future studies on clinical endpoints are needed to
find new drug–gene interactions. Identification of
more variants influencing susceptibility to drug-
induced QT interval prolongation might bring us
closer to tailored pharmacotherapy.
1 Introduction
The QT interval is measured on the electrocardiogram
(ECG) and represents the ventricular depolarization and
repolarization. The QT interval is usually corrected for
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heart rate, often using the formula of Bazett, as heart rate
influences the duration of the QT interval. Normally, the
average heart rate-corrected QT interval is approximately
410–430 ms for adult men and 420–430 ms for adult
women [1]. A prolonged heart rate-corrected QT interval is
usually defined as above 450 ms in men, and above 470 ms
in women [2]. A prolonged QT interval is a well known
risk factor for ventricular arrhythmias and sudden cardiac
death [3–6], and can be congenital or acquired [7, 8].
Congenital QT prolongation is caused by mendelian
genetic disorders, called the long QT syndromes. The long
QT syndromes can be divided into subtypes according to
the gene in which the causal mutation is located [9].
Acquired QT prolongation can be caused by cardiac dis-
eases, such as coronary heart disease and heart failure, but
it is usually caused by certain drugs [8, 10]. The suscep-
tibility to acquired QT interval prolongation can also be
influenced by genetic variation [9]. Two things point to
this: first, the heritability of QT interval duration in the
general population (excluding congenital long QT syn-
drome patients) is estimated to be around 35 % [11, 12],
and second, first-degree relatives of patients with congen-
ital long QT syndrome have a higher risk of drug-induced
QT prolongation than non-related individuals [13]. In
genome-wide association studies (GWAS), a great number
of genes associated with QT interval duration have been
identified [14–16]. The gene with the strongest signal
related to QT interval duration is the nitric oxide synthase 1
adaptor protein gene (NOS1AP), located on chromosome 1
[14–20], and is influencing impulse propagation [21]. Other
findings from GWAS included polymorphisms within
genes known to be mutated in congenital long QT syn-
dromes, genes associated with intracellular calcium han-
dling, as well as genes previously not known to influence
cardiac repolarization [9, 15, 16]. Because drug use is the
most common cause of acquired QT prolongation [7], QT
interval prolongation is an important outcome in drug
safety research [5, 6]. In drug safety studies, QT interval
prolongation is often combined with torsade de pointes, a
rare ventricular arrhythmia associated with QT prolonga-
tion. Drugs can lead to a relatively high frequency of tor-
sade de pointes, of up to 5 % [22]. QT interval
prolongation is one of the leading causes of drug relabeling
or withdrawal of drugs from the market [23, 24]. Drugs that
are associated with either QT prolongation or torsade de
pointes are mentioned in various lists, such as the
University of Arizona list [25, 26]. These lists include
antiarrhythmic drugs, such as flecainide and amiodarone,
but also non-cardiac drugs [25]. These non-cardiac drugs
are a diverse set with various indications and working
mechanisms and include antidepressant drugs (e.g.,
citalopram), antibiotics (e.g., erythromycin and fluoro-
quinolones), and drugs against nausea (e.g., domperidone)
[25]. Regulatory authorities state that these drugs should
not be administered to patients already using another drug
with QT-prolonging properties or to patients who have an
increased risk of QT prolongation [5, 6].
As QT interval duration is influenced by genetic vari-
ants, the individual risk of drug-induced QT interval pro-
longation may also be influenced by genetic factors.
Pharmacogenetics describes the role of genetic variation in
drug response, which can relate to both pharmacokinetic
and pharmacodynamic properties. Pharmacokinetics con-
stitute the effect of the body on the drug, which is usually
categorized into effects on absorption, distribution, meta-
bolism, and elimination of the drug. Pharmacodynamics
reflect the effect of the drug, in a certain concentration, on
the body. Both pharmacokinetics and pharmacodynamics
influence efficacy and effectiveness of the drug, and the
occurrence of adverse drug reactions. As genotyping has
become less expensive over the past years, larger popula-
tions can be investigated and more and more variants
determining susceptibility to drug-induced QT interval
prolongation could possibly be detected. This might bring
us closer to the goal of tailored pharmacotherapy [27].
Therefore, our objective was to provide an overview of the
pharmacogenetics of drug-induced QT interval prolonga-
tion. Hereto, we distinguished pharmacokinetic and phar-
macodynamic genetic susceptibility and ethnic differences
in QT interval prolongation. We searched PubMed from
inception until April 8, 2015 using the search terms
(pharmaco)genetic, (pharmaco)genomic, QT/QTc, pro-
long*, long, drug-induced, drug related, drug, medication,
medicine, ethnic, race. We applied a restriction for articles
in the English language.
An overview of the pharmacogenetics discussed in this
review is shown in Fig. 1 and an overview of the knowl-
edge on ethnic differences in susceptibility to QT prolon-
gation is given in Fig. 2.
2 Pharmacokinetic Genetic Susceptibility
A description of the pharmacokinetics of all QT-prolong-
ing drugs and interactions with other drugs is beyond the
scope of this review. We focused on the influence of genes
related to pharmacokinetics on drug-induced QT interval
prolongation.
2.1 Cytochrome P450 Substrates
Many drugs are metabolized in the liver by cytochrome
P450 (CYP), a family of enzymes. These enzymes are
encoded by various genes named according to their family
(e.g., ‘2’) and subfamily (e.g., ‘C’), based on the amino
acid structure. A full code indicates a specific gene, (e.g.,
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CYP2C9). A large proportion of the QT-prolonging drugs
are metabolized by CYP2D6, CYP3A4/5, and CYP2C9
[28]. Several cytochrome P450 genes have been investi-
gated in relation to drug-induced QT interval prolongation.
CYP2D6 is the most extensively studied gene of the
CYP family in relation to drug-induced QT prolongation.
Genetic variation within CYP2D6 was associated with QT
prolongation in users of risperidone and iloperidone [29–
31]. However, in users of haloperidol and thioridazine,
CYP2D6 status was not associated with QT prolongation
[32–35]. The proportion of poor metabolizers was not
different among users of the antispasmodic terodiline sur-
viving ventricular tachycardia or torsade de pointes than in
the total population [36].
Another often studied gene of the CYP family is
CYP2C19. CYP2C19 status was a predisposing factor for
QT prolongation in antimicrobial (except quinolones) users
[37] and a higher proportion of poor metabolizers was
found among terodiline users who survived ventricular
tachycardia or torsade de pointes compared with the nor-
mal population [36]. CYP2C19 status did not influence QT
interval in users of nelfinavir or thioridazine [35, 38].
Some other CYP family members were investigated.
Methadone users who were CYP2B6 poor metabolizers had
an increased QT interval duration and a 4.5-fold increased
risk of a prolonged QT interval compared with methadone
users who were normal or extensive metabolizers [39].
CYP2C9 was not associated with QT prolongation in
risperidone users [29]. CYP3A4 and CYP2C9 variants
predisposed to an increased risk of QT prolongation or
torsade de pointes induced by antimicrobial agents, with
the exception of quinolones [37].
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Fig. 1 Overview of the genes associated with drug-induced QT interval prolongation
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Fig. 2 Overview of the available knowledge on ethnic differences in susceptibility to drug-induced QT interval prolongation
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2.2 P-Glycoprotein
P-glycoprotein is a transmembrane efflux pump and influ-
ences bioavailability of several drugs. P-glycoprotein is
encoded by the ATP-binding cassette B1 gene (ABCB1)
[40]. The three most frequently investigated polymor-
phisms within this gene are C1236T, G2677T, and C3435T
[41–43]. In a study in 66 schizophrenia patients using
risperidone, the QT interval was significantly longer in
patients carrying a T allele of the C3435T polymorphism
than homozygous C allele carriers [44]. A study on romi-
depsin, a potentially QT-prolonging anticancer drug,
showed that mice lacking P-glycoprotein had higher
intracardiac concentrations of the drug. This study also
showed that carriers of genetic variants in ABCB1 have less
QT interval prolongation following a dose of romidepsin
[45]. Thus, P-glycoprotein might also be an effect modifier
of other potential QT-prolonging drugs.
3 Pharmacodynamic Genetic Susceptibility
3.1 Genes Known From Congenital Long QT
Syndrome
Five to nineteen percent of patients with drug-induced
torsade de pointes carry mutations in genes involved in
congenital long QT syndrome [46, 47]. These genes are
listed in Table 1, which also shows the number of studies
that did or did not find an association between these genes
and drug-induced QT interval prolongation or torsade de
pointes [31, 46–57]. Since the human ether-a-go-go (eag)-
related gene (hERG) channel and its associated gene, the
potassium channel, voltage gated eag-related subfamily H,
member 2 gene (KCNH2), were investigated most fre-
quently and are currently a topic of special interest in drug
safety research, it will be discussed separately.
3.1.1 hERG Channel Encoded by KCNH2
The hERG channel has received much attention in the past
decades. In congenital long QT syndrome type 2, the causal
mutation is located in the KCNH2 gene, which encodes this
channel [58]. KCNH2 encodes the a subunit of the channel
mediating the rapidly activating component of the delayed
rectifier K? (Ikr) current [59]. The hERG channel can be
blocked by drugs in two different ways: (1) direct blocking
of the channel; (2) indirect blockade by disrupting channel
protein trafficking through a reduction of the number of
channels in the membrane [58, 60]. The resulting inhibition
of the Ikr current in turn leads to an excessive lengthening
of the action potential. This can lead to early after depo-
larizations and subsequently to arrhythmias and sudden
cardiac death [61]. Almost all drugs that have been asso-
ciated with torsade de pointes or QT prolongation block the
Ikr current, but not all Ikr-blocking drugs have QT-pro-
longing properties [62]. In a study of 14 antipsychotics, a
significant correlation was reported between the estimated
hERG blockade and the increase in QT interval for five Ikr-
blocking drugs (haloperidol, olanzapine, risperidone,
thioridazine, and ziprasidone) [63]. Several studies identi-
fied mutations in the KCNH2 gene in persons with drug-
induced prolonged QT interval or torsade de pointes, which
were not present in controls [46, 47, 50, 52, 64]. These
were KCNH2 mutations not related to congenital long QT
syndrome type 2. Several KCNH2 mutations were identi-
fied in persons with drug-induced arrhythmias in a database
of a spontaneous reporting system for adverse drug reac-
tions [49]. However, in one study, persons with drug-in-
duced torsade de pointes had a similar proportion of hERG
mutations as controls [54] and three studies did not find an
association between KCNH2 and drug-induced QT pro-
longation [48, 51, 53]. In a study on dofetilide-induced
hERG blockade, it was reported that a blockade of 10 %
was associated with a 20-ms [95 % confidence interval (CI)
12–32] increase in QT interval [65]. A study in methadone
users showed that persons with a KCNH2 mutation had a
15-ms (95 % CI 5–26) longer QT interval [57].
3.1.2 Other Genes Known from Congenital Long QT
Syndrome
Several studies have assessed genes involved in congenital
long QT syndrome, to identify variants, other than the
causal ones in congenital long QT syndrome, that are
associated with drug-induced QT interval prolongation.
The design of these studies is very heterogeneous [31, 46–
57, 60]. For example, studies included methadone users
[57], cases of drug-induced arrhythmias from a database of
spontaneous reports of adverse drug reactions [49], and a
case report [51]. Results from these studies are ambiguous,
as not one gene has consistently been associated with drug-
induced QT prolongation. The fact that the study popula-
tions were small hampers the possibility to draw firm
conclusions.
3.2 Other Genes Having Pharmacodynamic Effects
3.2.1 NOS1AP
The NOS1AP gene encodes the nitric oxide synthase 1
activating protein and regulates the enzyme neuronal nitric
oxide synthase (nNOS), a regulator of intracellular calcium
levels and cardiomyocyte contraction [66, 67]. nNOS
inhibits L-type calcium channels and influences cardiac
repolarization [68] and impulse propagation [21]. Previous
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studies have shown that NOS1AP is associated with QT
interval duration [14–16, 69], and common variants within
this gene have been associated with an increased risk of QT
prolongation, induced by amiodarone, sotalol, or diuretics
[70]. As the NOS1AP gene is associated with inhibition of
L-type calcium channels, which are blocked by certain
calcium channel blockers (i.e., diltiazem and verapamil), it
can be expected that this gene modifies response to these
drugs. Two variants within the NOS1AP gene were asso-
ciated with a modified effect of the drug on QT interval
duration in users of verapamil and, to a lesser degree,
diltiazem [71]. NOS1AP has also been associated with
antipsychotic-induced QT prolongation [48] and drug-in-
duced torsade de pointes [56]. Heterozygous and
homozygous major allele carriers of the rs10494366 vari-
ant had an increased risk of a prolonged QT interval fol-
lowing granisetron or dolasetron administration in the
perioperative setting, compared with homozygous minor
allele carriers [72].
3.2.2 Other Candidate Gene Studies
Several other genes with suspected pharmacodynamic
effects were investigated for their association with drug-
induced QT prolongation or drug-induced torsade de
pointes. Selection of these genes was based on known
association with arrhythmias or cardiac diseases or because
of a suggestive or significant signal in a GWAS. The results
of the candidate gene studies are summarized in Table 2
[48, 52, 53, 56, 73].
4 Genome-Wide Association Studies (GWAS)
on Drug-Induced QT Interval Prolongation
In GWAS, associations are studied between a phenotype
and an extensive set of polymorphisms throughout the
whole genome. Generally, only a subset of all polymor-
phisms of a person are genotyped, after which the other
polymorphisms are imputed with a reference panel. The
most frequently used reference panels are HapMap [74, 75]
and 1000 Genomes [76–78]. HapMap contains around 2.5
million common polymorphisms; 1000 Genomes contains
around 30 million polymorphisms and includes both
common and rare variants. The choice of reference panel
can influence the number of findings and whether rare
variants can be identified. We describe this type of research
separately, because both pharmacokinetic and pharmaco-
dynamic polymorphisms can be detected with GWAS. We
also describe a whole-exome sequencing study, which is
Table 1 Genes known from congenital long QT syndrome, investigated in drug-induced long QT syndrome or torsade de pointes
cLQTS type Gene abbreviation Gene name [110] Gene protein product [9] Association founda
Yes No
cLQTS1 KCNQ1 Potassium channel, voltage gated KQT-like
subfamily Q, member 1 gene
IKs channel alpha-subunit 3 4
cLQTS2 KCNH2 Potassium channel, voltage gated eag-related
subfamily H, member 2
IKr channel alpha-subunit 9 4
cLQTS3 SCN5A Sodium channel, voltage gated, type V alpha-
subunit
INa channel alpha-subunit 3 4
cLQTS4 ANK2 Ankyrin 2, neuronal 1 1
cLQTS5 KCNE1 Potassium channel, voltage gated subfamily E
regulatory beta-subunit 1
IKs channel beta-subunit 4 3
cLQTS6 KCNE2 Potassium channel, voltage gated subfamily E
regulatory beta-subunit 2
IKr channel beta-subunit 2 6
cLQTS7 KCNJ2 Potassium channel, inwardly rectifying subfamily
J, member 2
IKl alpha-subunit 0 3
cLQTS8 CACNA1C Calcium channel, voltage-dependent, L type,
alpha-1C subunit
ICaL channel alpha-subunit 2 1
cLQTS9 CAV3 Caveolin-3 0 2
cLQTS10 SCN4B Sodium channel, voltage gated, type IV beta-subunit INa channel beta-subunit 4 1 1
cLQTS11 AKAP9 A kinase anchor protein 9 1 2
cLQTS12 SNTA1 Syntrophin, acidic 1 1 1
cLQTS13 KCNJ5 Potassium channel, inwardly rectifying subfamily
J, member 5
IKACh channel alpha-subunit 0 1
cLQTS congenital long QT syndrome
a Number of studies that did or did not find an association with the corresponding gene
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technically not a GWAS, but has a similar aim and
methodology.
There are two possible ways to investigate the genetic
basis of drug-induced QT prolongation in the framework of
GWAS [79]. The first is to investigate the association
between the polymorphism and a drug-induced phenotype.
The phenotype can be either a dichotomous clinically
relevant endpoint (e.g., a heart rate-corrected QT interval
above 450 ms in men and above 470 ms in women) [2] or a
continuous variable (e.g., the delta QT in ms before and
after exposure) [2]. The second is to perform drug–gene
interaction GWAS. In these analyses, the interactions
between the use of certain drugs and all genetic polymor-
phisms available in the reference panel are investigated in
Table 2 Genes investigated in
candidate gene studies on drug-
induced QT prolongation
Gene abbreviation Gene name [110] Association
founda
AKAP6 A kinase anchor protein 6 Yes [52]
AKAP7 A kinase anchor protein 7 Yes [52]
APLP2 Amyloid beta precursor-like protein 2 Yes [52]
ATP1B1 ATPase, Na?/K? transporting, beta 1 polypeptide No [48]
ATP2A2 ATPase, CA?? transporting, cardiac muscle, slow twitch 2 Yes [52]
– Beta-adrenergic receptor genes No [73]
BRUNOL4 Bruno-like 4 No [48]
CACNB2 Calcium channel, voltage-dependent, beta 2 subunit Yes [52]/No
[53]
CALR Calreticulin Yes [52]
CASQ2 Calsequestrin 2 Yes [56]
CERKL Ceramide kinase-like No [48]
CNOT1 CCR4-NOT transcription complex, subunit 1 No [48]
FKBP1B FK506 binding protein 1b No [56]
GINS3 GINS complex subunit 3 No [48]
GPD1L Glycerol-3-phosphate dehydrogenase 1-like Yes [52]/No
[53, 56]
JPH2 Junctophilin 2 Yes [52]
JPH3 Junctophilin 3 Yes [52]
KCND3 Potassium channel, voltage gated Shal related subfamily D, member
3
Yes [52]
KCNN3 Potassium channel, calcium activated intermediate/small
conductance subfamily N alpha, member 3
Yes [52]
LIG3 Ligase III, DNA, ATP-dependent No [48]
LITAF Lipopolysaccharide-induced TNF factor No [48]
NDRG4 NDRG family member 4 No [48]
NRG3 Neuregulin 3 No [48]
NUBPL Nucleotide-binding protein-like Yes [48]
PALLD Palladin, cytoskeletal associated protein No [48]
PLN Phospholabam No [48]
PPP2R3A Protein phosphatase 2, regulatory subunit beta, alpha Yes [52]
RNF207 Ring finger protein 207 No [48]
RYR2 Ryanodine receptor 2 Yes [52, 56]/
No [53]
SCN1B Sodium channel, voltage gated, type I beta subunit Yes [56]/No
[53]
SCN4A Sodium channel, voltage gated, type IV alpha subunit Yes [56]
SETD6 SET domain containing 6 No [48]
SLC35F1 Solute carrier family 35, member F1 No [48]
SLCO3A1 Solute carrier organic anion transporter family, member 3A1 No [48]
ZFHX3 Zinc finger homeobox 3 Yes [52]
a Association, enrichment or predictive value detected for this gene
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relation to QT interval as continuous outcome or a pro-
longed QT interval or torsade de pointes as dichotomous
outcome. However, for drug–gene interaction GWAS, very
large study populations are required [79]. Moreover,
because multiplicative models are tested, biologically rel-
evant interactions, which are usually additive, may be
missed.
4.1 GWAS on Drug-Induced QT Interval
Prolongation
A GWAS in 216 torsade de pointes cases caused by
amiodarone, sotalol, and quinidine and 771 controls, using
both HapMap and 1000 Genomes imputed data, did not
show genome-wide significant associations [80]. In another
GWAS in 738 subjects included in a randomized clinical
trial using approximately 600,000 polymorphisms, an
association was found between the solute carrier family 22
member 23 gene (SLC22A23) and antipsychotic-induced
(specifically quetiapine) QT prolongation [48]. SLCO3A1,
another member of this family, was associated with QT
interval prolongation induced by the antipsychotic
iloperidone in 183 subjects included in a randomized trial
[81]. This solute carrier family encodes organic ion trans-
porters that shuttle drugs across the cell membrane and are
expressed in cardiac tissue [48, 81]. Five other genes were
identified in the GWAS on iloperidone-induced QT pro-
longation using about 300,000 polymorphisms. These
included the ceramide kinase-like gene (CERKL), the pal-
ladin, cytoskeletal-associated protein gene (PALLD), the
bruno-like 4 gene (BRUNOL4), the neuregulin 3 gene
(NRG3), and the nucleotide-binding protein-like gene
(NUBPL) [81]. CERKL regulates currents of various
potassium channels, including the hERG channel. PALLD
has been associated with myocardial infarction. BRUNOL4
is expressed in cardiac tissue and has been associated with
cardiac structure and function. NRG3 has been found to
play a role in cardiac development. The role of NUBPL is
unclear [81]. Of these six genes, only the association
between NUBPL and drug-induced QT prolongation could
be replicated in another study [48]. A whole-exome
sequencing study in 65 cases and 148 controls revealed two
genes, KCNE1 and ACN9, associated with antiarrhythmic
and antipsychotic drug-induced QT interval prolongation
[53].
4.2 Drug–Gene Interaction GWAS
To our knowledge, there is only one drug–gene interaction
GWAS on QT interval duration. This study investigated the
interaction between genome-wide genetic variation using
HapMap imputed data and four types of exposure (thiazide
diuretics, tri/tetracyclic antidepressants, sulfonylurea
hypoglycemic agents, and QT-prolonging drugs) in 33,781
participants from ten cohort studies. It did not show a
genome-wide significant association with QT interval.
There were also no significant interactions with 26 poly-
morphisms previously reported to be related to QT interval
duration [82].
5 Ethnic Differences in Susceptibility
to Drug-Induced QT Interval Prolongation
As ethnic differences ultimately reflect genetic variation, it
is useful to study ethnicity with regard to susceptibility to
drug-induced QT interval prolongation. However, the role
of ethnic differences has not been well established in
studies on drug-induced QT interval prolongation. In 20
thorough QT/QTc studies, only 10 % of the total study
populations was African American and only 7 % was
Asian [83]. We will discuss studies that have investigated
the association between ethnicity and QT interval duration,
ethnicity and genes associated with QT interval, the
influence of ethnicity on associations between drugs and
QT interval, and the influence of ethnicity on drug–gene
interaction associated with QT interval. This is summarized
in Fig. 2.
5.1 Ethnic Differences in QT Interval Duration
Data on baseline differences of QT interval between dif-
ferent ethnicities is sparse. The available data indicates that
there are no large differences in the normal range [24]. A
difference of 6–7 ms was demonstrated for Asian women
in the normal range of the QT interval compared with other
ethnicities, and this was a difference of 10 ms in the upper
range of the QT interval [84]. Among 41 African Ameri-
cans and 3456 Caucasians with a prolonged QT interval,
African Americans had a 29-ms longer heart rate-corrected
QT interval [85].
5.2 Ethnic Differences in Genetic Variation
Associated with QT Interval
The frequency of polymorphisms in genes known from
congenital long QT syndrome had varying distributions
among ethnic groups [86–89]. A study on SCN5A showed
that out of the 39 variants found, 20 were only found in
African Americans, seven only in Caucasians, four only in
Asians, and three only in Hispanics. Only one polymor-
phism was found in all four ethnic groups [86, 88]. Of the
49 polymorphisms identified in KCNQ1, KCNH2, KCNE1,
and KCNE2, 27 were only found in African Americans, 13
only in Caucasians, two only in Asians, and two only in
Hispanics. Only two polymorphisms were identified in all
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four ethnic groups [87, 89]. A study on KCNH2 in 100
African Americans and 100 Caucasians, showed that the
minor alleles of two polymorphisms were more frequent
among Caucasians than among African Americans [89].
These studies only described the frequency of variants, but
not a potentially causal role of these genes with regard to
QT interval prolongation.
Contradictory results were published on the effect of
genetic variants on QT between different ethnicities.
Among Caucasians, more variants of 28 tagging SNPs of
the NOS1AP gene were significantly associated with QT
interval than in African Americans, Hispanics, and Chi-
nese [90]. However, other studies reported comparable
associations between NOS1AP gene variants and QT
interval among Caucasians, Hispanics, and African
Americans [91, 92], but also among African Americans of
both European and African ancestry [93]. Comparable
associations in different ethnic groups were also reported
between genetic variants of PLN1, KCNQ1, NDRG4, and
ATP1B1 and QT interval [92, 93]. However, one study
identified variants within NOS1AP and ATP1B1 among
African Americans that had not been reported in Cau-
casians [92].
5.3 Ethnic Differences in Drug Response
with Regard to QT Prolongation
African Americans had the highest risk of a prolonged QT
interval after acute overdose of QT-prolonging drugs [odds
ratio (OR) 2.01; 95% CI 1.03–3.91] while Hispanics had
the lowest risk (OR 0.49; 95% CI 0.26–0.92) compared
with all other ethnicities [94]. For the other ethnicities, no
statistically significant differences were observed [94].
Another study showed that Caucasians using quinidine, a
powerful QT-prolonging drug, were more sensitive to QT
prolongation than African Americans, even though base-
line values of the QT interval were comparable [95, 96].
Moxifloxacin is often used as positive control in thorough
QT/QTc studies and is a moderately powerful QT-pro-
longing drug. Studies showed that there were no ethnic
differences in QT prolongation following moxifloxacin and
levofloxacin administration [97–100], however the trend
suggested that Caucasians may be more sensitive to QT
prolongation than Asians [100].
5.4 Ethnic Differences in Drug–Gene Interaction
on QT Interval
One study compared the interaction between quetiapine use
and polymorphisms of the SLC22A23 gene on QT interval
and found a stronger effect of this drug–gene interaction in
Caucasians than in African Americans [48].
6 Discussion and Conclusion
Nowadays, QT interval prolongation is one of the most
common reasons to withdraw drugs from the market. Many
risk factors for QT interval prolongation and associated
arrhythmias have been identified, including both non-ge-
netic and genetic risk factors [3, 9, 10]. As QT-prolonging
effects might only occur in people with certain genetic
variations [24], drugs can be completely withdrawn from
the market, while they could be safe and beneficial for
certain patients. With more knowledge on the genetic
variation associated with drug-induced QT interval pro-
longation, we might be able to identify which patients
would benefit, and which patients would be at risk, and
subsequently not have to withdraw drugs with QT-pro-
longing properties from the market completely [101].
Pharmacovigilance studies focus on drugs that have come
onto the market and thus do not have extreme QT-pro-
longing properties. Therefore, we mostly detect genetic
variants with small effects. However, studies into the
genetic variation associated with extreme or frequent
adverse effects in early-phase studies could tell us more
about genetic variants with large effects. Genetic variants
associated with large adverse drug effects might be an
important aid in risk stratification, give insight into the
genes and proteins relevant for drug-induced QT interval
prolongation and arrhythmias, or ultimately result in
genetic targeted marketing (in accordance with cancer
pharmacogenetics) if the effect is fully dependent on a
genotype. However, other independent risk factors besides
genetic variants play a role in the development of a pro-
longed QT interval, which are important for risk stratifi-
cation in individual patients.
GWAS have been instrumental in the discovery of a
wide range of associations between genetic variants and
many different phenotypes. However, gene–environment
interaction GWAS are challenging, because of the large
sample size that is required for these kind of studies [79].
Therefore, in the field of pharmacogenetics, candidate gene
studies are probably more feasible. These studies are used
to elaborate on the possible mechanisms through which
drug-induced QT prolongation occurs. They may also shed
light on the large interpersonal variability in drug response
and therefore add to safer use of many drugs. However,
GWAS will remain an important tool for hypothesis gen-
eration. Power can be gained by improving the outcome
and exposure definition, leading to a reduction in mis-
classification. Nowadays, QT-prolonging drugs are inves-
tigated as one exposure group, often because of the low
number of exposed persons; for example, in the drug–gene
interaction GWAS by Avery et al. [82]. If the pathways
through which these drugs cause QT prolongation comprise
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the same genetic variants, this approach works. However, if
the working mechanisms are heterogeneous, exposure is
misclassified and this will reduce power to detect mean-
ingful variants.
Future research could focus on identifying which poly-
morphisms within a gene have the best predictive value for
adverse effects, the so-called fine mapping. With the
emergence of whole-genome sequencing and whole-exome
sequencing in large cohort studies [102], we will be able to
study genotypes in more detail and we will have data
available on more rare variants [102]. This might enable us
to discover more polymorphisms associated with adverse
drug reactions, which might also increase the predictive
value of polymorphisms that are important in pharmaco-
genetic interactions. The increasing availability of expres-
sion and methylation data in cohort studies might enable us
to determine epigenetic variants influencing the occurrence
of disease. Expression and methylation variants might also
be associated with the age at which QT prolongation occurs.
Future pharmacogenetic research should also focus on
direct clinical endpoints, such as arrhythmias, overall
mortality, and sudden cardiac death. This will tell us more
about the direct value of pharmacogenetic interactions for
daily clinical practice. A research method which is cur-
rently emerging is the molecular autopsy [103, 104]. In
cases of sudden death, without obvious causes identified
with autopsy, the pathologist can only assume that death
had an arrhythmogenic origin [103]. In these cases, geno-
typing family members or the deceased can shed light on
the genetic variation which might be the underlying factor
that caused the arrhythmia and death [103]. This research
method could provide more insight into genetic variations
associated with sudden deaths.
Concerns about the value of the QT interval in the pre-
diction of drug-induced arrhythmias and sudden cardiac
death have been highlighted in recent years, because some
drugs are associated with QT prolongation but not with an
increased risk of arrhythmias [105, 106]. In addition to
identifying genetic variation contributing to drug-induced
QT prolongation, we should also focus on identifying other
measurable markers, such as heart-rate variability [107] and
QT variability [108], and their genetic determinants of drug-
induced arrhythmia in order to improve risk prediction.
Since ethnic differences might be important for indi-
vidual-specific risk of drug-induced QT prolongation, more
research is needed to establish which drugs can be used
safely in the different ethnic groups. The studies mentioned
thus far suggest that Caucasians are more sensitive to drug-
induced QT interval prolongation than other ethnicities.
However, studies do not provide consistent results, possi-
bly because other risk factors besides genetic variants play
an important role in QT interval prolongation. Shah
hypothesizes that given the fact that the differences
between ethnicities in these studies are generally small,
ethnic differences are probably relatively most important in
users of mild QT-prolonging drugs [24]. If a drug has
strong QT-prolonging properties in general, it is not likely
that the small difference related to ethnicity will make
much difference. If a drug has no QT-prolonging properties
in general, it is not likely that it will be a cause of strong
QT prolongation in one ethnic group. However, if a drug
has moderate QT-prolonging properties, the small differ-
ences could mean that a drug can be used safely in some
ethnic groups, but not in others, because the degree of QT
prolongation is either just above or just below the safety
cut-off value [24]. The US FDA considers an increase
below 5 ms as not clinically relevant [6]. If, for example, a
drug prolongs the QT interval with 3 ms in one ethnicity,
while it causes an extra 3 ms increase in another ethnicity,
the added prolongation is small, but it will be just above the
safety cut-off value, meaning that the drug should be
contraindicated in one ethnicity, but not in the other. One
might question whether such a far-reaching consequence
would be justified considering the limited amount of
available information. In addition, within each ethnic
group, genetic modifiers can be different and pharmaco-
genetic studies should therefore not be limited to Cau-
casians only.
As genotyping has become less expensive over the last
couple of years, genotyping patients for genetic variants
that influence their risk of adverse drug effects has become
more feasible. This will allow us to investigate larger
populations, enabling us to find more, and also rare, genetic
variants. If we know the genetic profile of a patient with
regard to adverse drug effects, we might be able to pre-
scribe drugs more safely. This would also allow us to be
more accurate in the dosage that a patient needs [101].
However, clinical validity has to be tested for specific
drugs, as this has often been done insufficiently to date
[109]. Of course, many ethical, legal, and financial prob-
lems have to be solved before this can be applied in clinical
practice. But as it becomes more and more clear that
genetic variation is an important effect modifier when
prescribing several drugs, we should continue to identify
pharmacogenetic interactions and study their clinical
consequences.
In conclusion, we provided an overview of the most
important pharmacogenetic background of drug-induced
QT interval prolongation, which includes pharmacokinetic
and pharmacodynamic variants. GWAS have been proven
challenging because of the required large sample size.
However, with the availability of genetic data in more and
more large study populations, this method remains
important for hypothesis generation. Findings from these
studies can then be used for candidate gene studies to
further elaborate on possible drug–gene interactions. Not
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much data is available on ethnic differences in suscepti-
bility to drug-induced QT interval prolongation, although
Caucasians seem to be more sensitive to QT prolongation
than other ethnicities. Future research could focus on fine
mapping of genetic regions, epigenetics, clinical endpoints,
or use of alternative markers for drug-induced arrhythmias.
Knowledge on the genetic variants associated with drug-
induced QT interval prolongation is important as this will
provide more accurate predictions as to which patients will
experience the adverse drug effect and to whom the drugs
can be prescribed relatively safely. This may also prevent
unnecessary withdrawal of drugs from the market.
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